A critical component of the mission of the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) is to offer patients the best and most personalized treatments available. The overall goal of the Clinical Protocol and Data Management (CDPM) is to establish and maintain the resources and processes to centralize and integrate the multidisciplinary component, and multidepartmental activities required to run and oversee a broad portfolio of clinical trials, including national cooperative group trials, other NCI/CTEP- sponsored trials and investigator-initiated trials developed through members? translational research. An overarching theme is to ensure adequate enrollment of women, minorities, and children on our studies. The backbone of these operations is the Cancer Clinical Trials Office (CCTO), which is responsible for a) regulatory management for all adult cancer clinical trials, b) protocol tracking and management through a centralized Clinical Trials Management System (Velos eResearch); c) affiliate institution coordination and oversight, including 7 National Clinical Trials Network (NCTN) and Personalized Cancer Care Consortium affiliate networks, as well as over 40 additional ad hoc institutions; and d) quality control through centralized education and training, and formalized data and safety monitoring. We have well-established guidelines and a training manual for orientation of new regulatory managers as well as a centralized website with training videos, reference materials and Standard Operating Procedures (SOPs). The Office interacts closely with the UCCCC Information Technology Group, the Protocol Review and Monitoring System and the IRB. In 2016, the CCTO opened 152 new protocols (24% were investigator-initiated); a total of 914 patients were enrolled on therapeutic trials with 19% being minority (13% African American) and 48% women; 3286 patients were on non-interventional trials, with 49% minority (46% African American) and 56% women. Over the current grant cycle, we have streamlined and strengthened our audit program and instituted a number of efforts to increase accrual to trials including: e-newsblast to referring physicians, reformatting public-facing clinical trials listing on the UCCCC website, and development of new education and training materials, as well as building clinical trials infrastructure in our growing off-site network affiliates. Over the next five years, we plan to continue on this trajectory of improved and more efficient service, as well as to develop new services as needed. Major University of Chicago Medicine strategic initiatives, such as the additions to our integrated to network, as well as our network of off-site locations will necessitate continued expansion and refinement of our clinical research infrastructure including: a) Expansion of clinical trial access and functionality at network sites; b) Continued development and implementation of strategies to increase patient accrual; and c) Building on existing integration with Departmental research staff (e.g., data managers and nurses) through training and joint SOPs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-44
Application #
9701157
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-04-01
Budget End
2020-03-31
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Johnson, Marianna B; Hoffmann, Joscelyn N; You, Hannah M et al. (2018) Psychosocial Stress Exposure Disrupts Mammary Gland Development. J Mammary Gland Biol Neoplasia 23:59-73
Sweis, Randy F; Zha, Yuanyuan; Pass, Lomax et al. (2018) Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer 6:24
Kathayat, Rahul S; Cao, Yang; Elvira, Pablo D et al. (2018) Active and dynamic mitochondrial S-depalmitoylation revealed by targeted fluorescent probes. Nat Commun 9:334
Liu, Jun; Eckert, Mark A; Harada, Bryan T et al. (2018) m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol 20:1074-1083
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966
Sample, Ashley; Zhao, Baozhong; Wu, Chunli et al. (2018) The Autophagy Receptor Adaptor p62 is Up-regulated by UVA Radiation in Melanocytes and in Melanoma Cells. Photochem Photobiol 94:432-437
Hrusch, C L; Manns, S T; Bryazka, D et al. (2018) ICOS protects against mortality from acute lung injury through activation of IL-5+ ILC2s. Mucosal Immunol 11:61-70
Hope, C Matthew; Webber, Jemma L; Tokamov, Sherzod A et al. (2018) Tuned polymerization of the transcription factor Yan limits off-DNA sequestration to confer context-specific repression. Elife 7:
Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977

Showing the most recent 10 out of 668 publications